Premier Path Wealth Partners LLC Has $1.04 Million Stake in GSK plc (NYSE:GSK)

Premier Path Wealth Partners LLC grew its holdings in shares of GSK plc (NYSE:GSK) by 4.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,068 shares of the pharmaceutical company’s stock after purchasing an additional 1,148 shares during the period. Premier Path Wealth Partners LLC’s holdings in GSK were worth $1,042,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. International Assets Investment Management LLC acquired a new position in GSK in the 4th quarter valued at $7,024,000. abrdn plc acquired a new stake in shares of GSK in the 4th quarter valued at $1,551,000. GAMMA Investing LLC acquired a new position in shares of GSK during the fourth quarter worth $109,000. Cumberland Partners Ltd acquired a new stake in shares of GSK in the fourth quarter valued at about $741,000. Finally, Yousif Capital Management LLC raised its position in shares of GSK by 7.6% during the fourth quarter. Yousif Capital Management LLC now owns 36,256 shares of the pharmaceutical company’s stock worth $1,344,000 after acquiring an additional 2,555 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on GSK shares. Jefferies Financial Group upped their target price on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Finally, The Goldman Sachs Group assumed coverage on GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price on the stock. Three analysts have rated the stock with a hold rating, two have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $50.00.

GSK Stock Up 1.6 %

GSK stock traded up $0.68 during midday trading on Friday, reaching $42.63. The stock had a trading volume of 3,780,536 shares, compared to its average volume of 3,539,795. The company has a fifty day moving average price of $39.82 and a two-hundred day moving average price of $41.51. The company has a market capitalization of $88.35 billion, a P/E ratio of 15.45, a PEG ratio of 1.32 and a beta of 0.64. The company has a current ratio of 0.82, a quick ratio of 0.58 and a debt-to-equity ratio of 0.99. GSK plc has a 12 month low of $33.67 and a 12 month high of $45.92.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be issued a $0.3843 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.61%. The ex-dividend date is Friday, August 16th. GSK’s dividend payout ratio (DPR) is currently 54.71%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.